Skip To Content

Participating in open and frank conversations can be a catalyst for both positive change and a better industry. As we share our perspective you will find:

  • Relevant and timely industry information
  • Medication trends, and their impact
  • Case studies, and the results of their related projects
  • Special-subject on-demand webinars

Articles, blogs and podcasts 

Sharing information with the industry is an important part of our mission. Our subject matter experts translate today’s news into comprehensive informational pieces to help you better understand the impact of a recent industry update, trend, or issue.

January 19, 2022 · Public Policy & Regulatory Affairs Team
Read more...
January 04, 2022 · Medicare Insights Team
One year after it was signed into law, the Provide Accurate Information Directly ("PAID") Act went live on December 11, 2021. The Act requires the Centers for Medicare & Medicaid Services (CMS) to expand its process to identify whether a claimant is currently or has– in the last three years– been enrolled in Medicare Part C and/or Medicare Part D coverage. With this information, insurers can better identify a claimant’s Medicare plans and avoid unnecessary litigation. Read more...
December 15, 2021 · Public Policy & Regulatory Affairs Team
This month, the Policy Guys go head-to-head in a Battle of Wits to determine the ULTIMATE POLICY GUY as they show off what they know about Recent New York Work Comp Policy Developments. During this intense game show, The Policy Guys battle to prove who knows more about the New York Drug Formulary Change, OnBoard Limited Release and the DMEPOS fee schedule. Plus, you will get to meet the Policy Gal! Read more...
December 14, 2021 · Public Policy & Regulatory Affairs Team
The California Division of Workers’ Compensation (DWC) updated their Medical Treatment Utilization Schedule (MTUS) to incorporate by reference the Low Back Disorders Guideline from the American College of Occupational and Environmental Medicine (ACOEM). Read more...
December 09, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a new medication to prevent episodic migraine (fewer than fifteen headache days per month) on September 28, 2021. This approval allows AbbVie, Inc. to market Qulipta - a once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist - for migraine prevention. Qulipta is not indicated for the acute treatment of migraines like other oral CGRP receptor antagonists on the market, such as Ubrelvy™ (ubrogepant) and Nurtec® ODT (rimegepant). Qulipta is the second oral CGRP receptor antagonist to be approved for prevention of episodic migraine. Read more...
December 09, 2021 · Medicare Insights Team
The U.S. Food and Drug Administration (FDA) approved a new medication to prevent episodic migraine (fewer than fifteen headache days per month) on September 28, 2021. This approval allows AbbVie, Inc. to market Qulipta - a once daily oral calcitonin gene-related peptide (CGRP) receptor antagonist - for migraine prevention. Qulipta is not indicated for the acute treatment of migraines like other oral CGRP receptor antagonists on the market, such as Ubrelvy™ (ubrogepant) and Nurtec® ODT (rimegepant). Qulipta is the second oral CGRP receptor antagonist to be approved for prevention of episodic migraine. Read more...
     Next >>
Page 1 of 17

Subscribe today to receive our latest blogs, articles, podcasts and more.